BROSSARD, Quebec, July 04, 2018 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK), (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today an expansion of its screening services with the Mexican government in one northern state of Mexico. As per the agreement, DIAGNOS plans to screen 10,000 patients by December 31, 2018.
“In Mexico, a large portion of our government’s budget and expenses is going towards the medical treatment of two major problems for our patients’ health; diabetes and hypertension. Our objective is to collaborate with DIAGNOS in order to provide a preventive and a better way of monitoring our patients health”, said the Chief Medical Officer of the state. The Chief Medical Officer of the state also added: “We strongly believe that this preventive approach will strongly benefit our patients and generate substantial savings in future healthcare costs”.
The project consists of the screening of 10,000 patients by December 31, 2018, with a vision to extend the project for the following years. “We have been working with the diabetes team at the state level, and are able to provide the right solution at the right time”, said Guillermo Moreno, Vice-President at DIAGNOS.
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (“POC”). CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
For further information, please contact:
|André Larente, President||Josh Falle|
|DIAGNOS Inc.||Momentum PR|
|Tél. : 450 678-8882, poste 224||Tel: 514-416-4656|
|[email protected]||[email protected]|
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.